Error message

  • User warning: The following module is missing from the file system: entity. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/bootstrap.inc).
  • User warning: The following module is missing from the file system: entity_token. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/bootstrap.inc).
  • User warning: The following module is missing from the file system: path_breadcrumbs. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/bootstrap.inc).
×

COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

June 29, 2016
Proteogenomics Identifies New Biology in Ovarian Cancer and Insights to Diagnosis, Treatment

June 29, 2016 — In what is believed to be the largest study of its kind, scientists at Johns Hopkins University (JHU) and Pacific Northwest National Laboratory (PNNL) led a multi-institutional collaborative project that comprehensively examined the collections of proteins in the tumors of 169 ovarian...
May 25, 2016
First Large-Scale Proteogenomic Study of Breast Cancer Provides Insight into Potential Therapeutic Targets

News Release: May 25, 2016 — Building on data from The Cancer Genome Atlas (TCGA) project, a multi-institutional team of scientists has completed the first large-scale “proteogenomic” study of breast cancer, linking DNA mutations to protein signaling and helping pinpoint the genes that drive cancer...
December 28, 2015
Notice of Changes to RFA-CA-15-022 and Pre-Application Webinar

The National Cancer Institute will hold a public Pre-Application webinar on Wednesday, January 13, 2016 at 12:00 p.m. (EST) for the Funding Opportunity Announcement (FOA) RFA-CA-15-022 entitled “Proteogenomic Translational Research Centers for Clinical Proteomic Tumor Analysis Consortium (U01).”
November 19, 2015
Notice of Pre-Application Webinar (RFA-CA-15-021, RFA-CA-15-022, RFA-CA-15-023)

The National Cancer Institute will hold a public pre-application webinar on Friday, December 11 at 12:00 p.m. (EST) for the Funding Opportunity Announcements (FOAs) RFA-CA-15-021 entitled “Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24), RFA-CA-15-022 entitled...
October 30, 2015
NCI Requests Targets for Monoclonal Antibody Production and Characterization

In an effort to provide well-characterized monoclonal antibodies to the scientific community, NCI's Antibody Characterization Program requests cancer-related protein targets for affinity production and distribution.


Submissions will...
September 18, 2015
NCI Blog Post: CPTAC, the Complementary Sibling of TCGA (An Interview with Dr. Henry Rodriguez about NCI’s Proteomics Program)

What is proteomics? Proteomics is a highly automated and rapid method for measuring all the proteins in a biological sample. Proteins are the molecules that actually do most of the work inside a cell. When researchers develop cancer drugs, those drugs typically target proteins, so scientists and...
August 17, 2015
CPTAC Establishes Formal Relationships with Two Academic Institutions in Taiwan

The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) has entered into memorandum of understandings (MOUs) with Chang Gung University and Academia Sinica, in Taipei, Taiwan.
August 4, 2015
New Funding Opportunity: Tissue Purchase Order Acquisitions

The National Cancer Institute (NCI) is expanding its basic and translational research programs that rely heavily on sufficient availability of high quality, well annotated biospecimens suitable for use in genomic and proteomic studies.  The NCI’s overarching goal with such programs is to improve the...
July 8, 2015
New Funding Opportunity: Biospecimen Core Resource

The purpose of this notice is to notify the community that the National Cancer Institute's (NCI’s) Office of Cancer Clinical Proteomics Research (OCCPR) is seeking sources to establish a Biospecimen Core Resource (BCR), capable of receiving, qualifying, processing, and distributing annotated...
June 29, 2015
Pharmacodynamic Assay Panel for Monitoring Phospho-Signaling Networks

The DNA damage response (DDR) is a highly regulated signal transduction network that orchestrates the temporal and spatial organization of protein complexes required to repair (or tolerate) DNA damage (e.g., nucleotide excision repair, base excision repair, homologous recombination, non-homologous...

Pages

more

View all News and Announcements